Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL)
Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 582-584
10.1002/hon.3164_437